- Older type 2 diabetes (T2D) medications still remain the most frequently prescribed.
Why this matters
- Previous studies examining T2D medication trends are outdated or used limited populations.
- A recent joint statement advises assessing glycemia control, hypoglycemia risk, weight gain, cardiovascular effects, cost, and patient preferences of T2D medications.
- Data from 2008-2015 Medical Expenditure Panel Survey of diabetes medication utilization among adults with diabetes.
- Funding: None.
- Overall diabetes medication use rose from 81.4% in 2008 to 89.8% in 2012, then stabilized at 87.1% in 2015.
- Metformin use rose from 47.8% in 2008 to 60.0% in 2014, and stabilized to 59.4% in 2015.
- Insulin use increased from 22.6% in 2008 to 30.0% in 2015.
- Sulfonylurea use declined from 36.1% to 28.6% in 2014 and stabilized at 29.1% in 2015, while thiazolidinedione dropped from 21.4% in 2008 to 9.8% in 2015.
- Use of newer classes increased from 2008 to 2015, including dipeptidyl peptidase-4 inhibitors (6.2%-12.4%) and glucagon-like peptide-1 receptor agonists (2.5%-4.4%).
- Sodium glucose transporter-2 inhibitor use rose from 0.4% following approval in 2013 to 4.2% in 2015.
- No data on prior treatment failures, glycemic control, or therapy appropriateness.
- Inconsistent reporting for individual medications.